A statement released earlier today by Zacks Investment Research about ICU Medical, Incorporated (NASDAQ:ICUI) bumps the target price to $141.00
- Updated: September 24, 2016
ICU Medical, Incorporated (NASDAQ:ICUI) had its target price raised to $141.00 by Zacks Investment Research in a report released 9/21/2016. The new target price indicates a possible upside of 0.12% from the company's most recent close.
Having a price of $125.50, ICU Medical, Incorporated (NASDAQ:ICUI) traded 0.00% even on the day. The last closing price is up 14.86% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. The company has recorded a 50-day moving average of $124.15 and a 200-day moving average of $109.99. 89,703 shares of ICUI traded hands, down from an average trading volume of 97,861
Recent Performance Chart
ICU Medical, Incorporated has a 52 week low of $85.56 and a 52 week high of $128.93 with a P/E ratio of 37.62 The company’s market cap is currently $0.
A total of 5 analysts have released a research note on ICUI. Two analysts rating the company a strong buy, three equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero brokerages rating the company a sell with a 12-month price target of $131.80.
General Company Details For ICU Medical, Incorporated (NASDAQ:ICUI)
ICU Medical, Inc. is engaged in the development, manufacturing and sales of medical devices used in infusion therapy, oncology and critical care applications. The Company's product line includes needlefree connection devices, closed system transfer devices (CSTD), needlefree closed blood sampling systems, disposable pressure transducer systems and hemodynamic monitoring systems. It operates through the segment, which is engaged in the development, manufacturing and sale of medical technologies used in infusion therapy, critical care and oncology applications. Its Infusion Therapy products include MicroClave and MicroClave Clear, Neutron, NanoClave, Clave and SwabCap. Its Critical Care products include Hemodynamic Monitoring Systems, Closed Blood Sampling and Conservation Systems, and Other Critical Care Products and Accessories. Its Oncology products include ChemoLock CSTD and components, ChemoClave CSTD and components and Diana hazardous drug compounding system.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.